Overview

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if low dose radiation, which is routinely used in treating patients with lung cancer for symptom control, can improve the results from the standard treatment with pembrolizumab and chemotherapy. In this study, only individuals who have NSCLC that is advanced (Stage IV), or has come back (recurred), will be able to participate.
Phase:
Phase 2
Details
Lead Sponsor:
NYU Langone Health
Treatments:
Pembrolizumab